BMS Foundation, PRIDE ALLIANCE Fund Study to Address Healthcare Disparities
The COLORS Training Program aims to educate oncologists on healthcare disparities experienced in the LGBTQ+ community.
BMS to Acquire MyoKardia
We announced our agreement to acquire MyoKardia, whose portfolio of pipeline drug candidates includes mavacamten, a potential first-in-class medicine that shows compelling data in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Click here for an overview.
A subset of BMS.com, Life & Science Stories is where we share the work our global community of colleagues are doing around the world to help patients and advance scientific innovation.
Looking for Answers?
Quick links to helpful resources.